About DNA repair nuclease/redox regulator APEX1
DNA repair nuclease/redox regulator APEX1 (APEX1) is a protein
from Homo sapiens identified by UniProt accession
P27695, 318 residues long.
MolForge cross-references it against 0 known binders and
401 disease associations.
Target properties
| Protein name | DNA repair nuclease/redox regulator APEX1 |
| UniProt accession | P27695 |
| Gene | APEX1 |
| Organism | Homo sapiens |
| Length | 318 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (401)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- blood protein measurement · score 0.24
- breast adenocarcinoma · score 0.18
- cancer · score 0.12
- neoplasm · score 0.12
- hepatocellular carcinoma · score 0.11
- non-small cell lung carcinoma · score 0.11
- triple-negative breast cancer · score 0.11
- urinary bladder carcinoma · score 0.10
- esophageal adenocarcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P27695-F1 | alphafold | PREDICTED | 90.46 | — |
Amino-acid sequence (318 residues)
MPKRGKKGAV AEDGDELRTE PEAKKSKTAA KKNDKEAAGE GPALYEDPPD QKTSPSGKPA TLKICSWNVD GLRAWIKKKG LDWVKEEAPD ILCLQETKCS ENKLPAELQE LPGLSHQYWS APSDKEGYSG VGLLSRQCPL KVSYGIGDEE HDQEGRVIVA EFDSFVLVTA YVPNAGRGLV RLEYRQRWDE AFRKFLKGLA SRKPLVLCGD LNVAHEEIDL RNPKGNKKNA GFTPQERQGF GELLQAVPLA DSFRHLYPNT PYAYTFWTYM MNARSKNVGW RLDYFLLSHS LLPALCDSKI RSKALGSDHC PITLYLAL
Explore DNA repair nuclease/redox regulator APEX1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets